Cystic tumor ablation with different concentrations of lauromacrogol solution in an animal model
article
OA: closed
CC0
AI-generated summary
This study evaluated the efficacy and safety of different lauromacrogol concentrations for cystic tumor ablation in a rat endometriosis model, finding 1%, 2%, and 3% solutions effective and safe.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: Lauromacrogol, as a sclerosing agent, can induce aseptic inflammation and fibrous tissue proliferation to achieve sclerotherapy. Lauromacrogol is widely used not only for vascular sclerotherapy but also for the treatment of different cystic tumors. To evaluate the efficacy and safety of cystic tumor ablation with different concentrations of lauromacrogol solution in a rat endometriosis model, and explore the advantages and disadvantages of this model in simulating pancreatic cystic neoplasm.
METHODS: An endometriotic cyst model was established in 50 mature female Sprague-Dawley rats. After 4 weeks, successfully modeled cysts were randomly divided into four groups: group A, in which cyst were injected with normal saline; and groups B to D, in which cyst were injected with 1%, 2%, and 3% lauromacrogol solution, respectively. The rats were then fed for 4 more weeks. The abdominal cavity was opened to observe the morphology of the cyst and the degree of damage to surrounding organs. If the ablation procedure failed, the whole cyst was collected; if the ablation procedure was successful, residual scar tissue was collected. The ratio of ablated epithelial cells to the epithelial layer and the intactness of the lamina propria were observed by low- and high-power microscopy.
RESULTS: After ablation, the cysts in normal saline group showed a maintained hemispherical structure, whereas those in three different concentrations of lauromacrogol solution groups showed a flat scar. The effective rate of each group was statistically different. Pairwise comparison of corrected significance levels using the Bonferroni method showed statistically a significant difference between normal saline group and 1% lauromacrogol solution group, 2% lauromacrogol solution group and 3% lauromacrogol solution group.
CONCLUSIONS: According to the morphology and pathology of rat endometriotic cysts after ablation, it can be preliminarily concluded that ablation with 1%, 2%, or 3% lauromacrogol solution is an effective and safe therapeutic option. Rat endometriotic cyst model can simulate pancreatic cystic neoplasms to a certain extent.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- The effects of lauromacrogol injection into rat endometrial cysts: a preliminary experimental study 2016
- The effects of sclerotherapy with 5% trichloroacetic acid on the cyst diameter and ovarian tissue in the rat ovarian cyst model 2018
- Sclerotherapic effects of different concentrations of lauromacrogol on endometrial cyst models in rats in two retention ways 2015
References (28)
- Sclerotherapic effects of different concentrations of lauromacrogol on endometrial cyst models in rats in two retention ways via openalex
- The effects of lauromacrogol injection into rat endometrial cysts: a preliminary experimental study via openalex
- The effects of sclerotherapy with 5% trichloroacetic acid on the cyst diameter and ovarian tissue in the rat ovarian cyst model via openalex
- W2002069247 via openalex
- W2089480126 via openalex
- W2090579900 via openalex
- W2090755771 via openalex
- W2101439827 via openalex
- W2122441872 via openalex
- W2150028563 via openalex
- W2494813546 via openalex
- W2601984908 via openalex
- W2606143437 via openalex
- W2616683625 via openalex
- W2791664943 via openalex
- W2798191310 via openalex
- W2801777944 via openalex
- W2890029692 via openalex
- W2952178864 via openalex
- W2973193311 via openalex
- W3036539527 via openalex
- W3084164302 via openalex
- W3124115076 via openalex
- W3165248762 via openalex
- W1589549127 via openalex
- W4237167188 via openalex
- W1967971828 via openalex
- W1970847274 via openalex
Source provenance
- europepmc
- last seen: 2026-08-25T06:10:03.373225+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-08-25T06:08:50.992859+00:00
License: CC0
· commercial use OK